Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, Nilsson B, Moller JE, Hjort J, Rasmussen J, et al
You will receive 1 free month of BetterHelp when you become an OrderlyMeds customer
The GLP-1 biosimilars market is primarily driven by the rapidly increasing global prevalence of type 2 diabetes and obesity, rising demand for affordable biologic therapies, and the impending patent expirations of major originator GLP-1 drugs such as semaglutide and dulaglutide
Targeting more than one receptor seems to boost the medications weight-loss effects
We offer a personalized approach, tailoring the treatment to meet individual health and weight loss goals
Easy once-a-day use